Case Report

Hb Mazandaran (α1) α51 Gly > Cys(CE9), c.154 GGC > TGC: A Novel Haemoglobin Variant of α1-Globin Gene

Hossein Jalali 1,2, Mohammad Reza Mahdavi 1, *, Mahan Mahdavi 2 and Adeleh Abbasi 3

1 Thalassemia Research Center, Hemoglobinopathies Institute, Mazandaran University of Medical Sciences, Sari 4817993375, Iran; hossein.jalalakerdi@gmail.com
2 Sinaye Mehr Research Center, Sari 4817993375, Iran; mahanbiomedical@gmail.com
3 Nasiri Health Care Center, Fereydunkenar 4817993375, Iran; adelehabbasi@yahoo.com
* Correspondence: mahdavi899@gmail.com

Abstract: This is a report of a novel variant of the α1-globin gene—(α1) α51 Gly > Cys (CE9), c.154 GGC > TGC, named Hb Mazandaran, which was observed in an Iranian family. This variant gives rise to a previously undescribed haemoglobin variant that was undetectable by capillary haemoglobin electrophoresis (CE). This variant was detected in two cases in combination with β-globin mutation, and it does not seem to be associated with severe haematological abnormalities in the carriers.

Keywords: α-thalassemia; Hb Mazandaran; capillary electrophoresis

1. Introduction

Haemoglobin (Hb) disorders are a major worldwide global health concern, and it is estimated that around 7% of the world population are carriers of different kinds of haemoglobinopathies. Alpha-thalassemia (α-thal) is the most common Hb disorder around the world, with the highest incidence rate in South-East Asia, the Mediterranean and Middle Eastern populations, India, and sub-Saharan Africa [1]. In the north of Iran, about 15% of neonates are carriers of α-globin mutations [2]. Depending on the number of deleted copies or non-deletional mutations, the clinical presentations of the disease are varied, ranging from almost asymptomatic to lethal haemolytic anaemia [3].

More than 400 different structural variations of α-globin protein have been introduced, most of which are not associated with noticeable clinical manifestation [3]; however, some can affect the function of the Hb molecule and its stability, leading to erythrocytosis and haemolytic anaemia.

There is no genotype–phenotype correlation, even in the presence of a similar genotype in patients with α-thalassemia [3,4]. Hence, introduction of novel variants of the α-globin gene helps to collect comprehensive knowledge about thalassemia disease. The present study aimed to introduce a new H. variant caused as a result of mutation of the α1-globin gene.

2. Case Presentation

A 25-year-old male was referred to Fajr Medical Genetics Laboratory (Sari, Iran) for routine haematological analysis as part of a national screening program for beta thalassemia [5].

Complete blood count (CBC) and Hb capillary electrophoresis (CE) were carried out. After obtaining written informed consent from the patient, molecular analysis was conducted on genomic DNA extracted from peripheral blood using a QIAamp DNA Mini Kit (Qiagen, Germany). To identify common Mediterranean α-Globin gene deletions (~α3.7, ~α4.2, ~MED, and ~20.5), multiplex Gap-PCR was performed, and to detect other mutations of the α and β-Globin genes, the PCR sequencing method was used.
Haematological indices and CE results were compatible with being a β-thalassemia carrier (Figure 1, Table 1). Molecular analysis of α and β-globin genes indicated that the subject carried c.315 + 1G>A (IVSII-1G > A) and c.154G > T (p.Gly52Cys) mutations of the β and α1-globin genes, respectively (Figure 2). DNA analysis of the subject’s parents showed that the father did not carry the identified mutations; however, his mother carried both of the detected mutations. To the best of our knowledge, the c.154G > T (p.Gly52Cys) variant has not been reported in databases (Clin Var and USSC), and we named it Hb Mazandaran. In silico analysis using PolyPhen-2 software predicted the altered protein to be probably damaging (with a score of 1).

Table 1. Haematological indices of a case with co-inheritance of c.315 + 1G > A mutation of the β-globin gene and c.154G > T mutation of the α1-globin gene.

<table>
<thead>
<tr>
<th>RBC (×10⁶/µL)</th>
<th>Hb (g/dL)</th>
<th>Hct (%)</th>
<th>MCV (fl)</th>
<th>MCH (pg)</th>
<th>MCHC (g/dl)</th>
<th>Hb A1</th>
<th>Hb A2</th>
<th>Other Hb Variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proband</td>
<td>7.67</td>
<td>13.7</td>
<td>44.2</td>
<td>58.6</td>
<td>17.9</td>
<td>31.0</td>
<td>93.5</td>
<td>5</td>
</tr>
<tr>
<td>Mother</td>
<td>5.23</td>
<td>10</td>
<td>31.3</td>
<td>59.9</td>
<td>19.1</td>
<td>31.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Father</td>
<td>5.56</td>
<td>15.8</td>
<td>44.9</td>
<td>80.7</td>
<td>28.4</td>
<td>35.2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Mazandaran is a province of Iran located on the southern coastline of the Caspian Sea, and thalassemia is a common hereditary genetic disorder in that region [6]. Several variants of Hb, such as Hb D [7], Hb J-Toronto [8], Hb Fontainebleau [9], and Hb S [10], have also been reported in Mazandaran. In the present study, we report a novel variant of the α1-globin gene, Hb Mazandaran (α1) α51 Gly > Cys(CE9), c.154 GGC > TGC, detected in a family from Mazandaran, Iran. This mutation gives rise to a previously undescribed Hb variant that was undetectable via the CE technique.

To date, three different variants of Hb have been identified at codon 52 of the HbA1 gene, including Hb Riccarton (p.Gly51Ser) [11], Hb Russ (p.Gly51Arg) [12], and Hb J Abidjan (p.Gly51Asp) [13]. The presented case is the fourth identified Hb variant as a result of an amino acid change at codon 52 of the HbA1 gene. This variant was detected in two cases in combination with β-globin mutation, and it does not seem to be associated with severe haematological abnormalities in the carriers. Identification of all variants of Hb in different regions helps to collect comprehensive knowledge about thalassemia disease, and it can be used in preventive programmes and in prenatal diagnosis.

Author Contributions: M.M and H.J.; methodology, M.M.; software, A.A.; formal analysis, M.M, and A.A.; data curation, H.J and A.A.; writing—original draft preparation, M.R.M., writing—review and editing, M.R.M.; project administration. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no extra funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data can be made available upon request to the corresponding author.

Acknowledgments: The authors are grateful to Fatemeh Alizadeh, Bita Talebi and Maryam Rahimifor their assistance in sampling and writing of the manuscript. This case report was coordinated by Fajr Genetics and Pathobiology Laboratory.

Conflicts of Interest: The authors report no conflict of interest. The authors alone are responsible for the content and writing of this article.

References


